Western Wealth Management LLC Acquires 4,068 Shares of Gilead Sciences, Inc. $GILD

Western Wealth Management LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 104.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,949 shares of the biopharmaceutical company’s stock after buying an additional 4,068 shares during the quarter. Western Wealth Management LLC’s holdings in Gilead Sciences were worth $1,108,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in GILD. Paulson Wealth Management Inc. boosted its holdings in Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after purchasing an additional 67 shares during the last quarter. Essex Financial Services Inc. raised its stake in Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after buying an additional 71 shares during the last quarter. Davidson Trust Co. lifted its holdings in shares of Gilead Sciences by 4.1% during the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 74 shares during the period. Alpha Cubed Investments LLC boosted its stake in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 76 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead is partnering with Nucleai to deploy AI-powered tissue analytics across its global antibody-drug conjugate programs. The technology could accelerate biomarker discovery, standardize tumor-sample analysis and improve precision-oncology development, potentially strengthening Gilead’s longer-term pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Gilead exercised an option to exclusively license a preclinical bispecific program from MacroGenics, triggering a $10 million payment to its partner. The move expands Gilead’s oncology assets and signals continued investment in potential next-generation cancer treatments, although the program remains early stage. MacroGenics Announces $10 Million Milestone Following Gilead License
• Positive Sentiment: Analysts cited a consensus price target of $158.04, indicating potential upside relative to recent trading levels and continued confidence among covering analysts. Gilead Receives $158.04 Consensus Target Price
• Positive Sentiment: Gilead’s second-quarter revenue rose approximately 10% year over year to $7.8 billion and exceeded expectations. The reported loss was primarily affected by an $11.2 billion one-time acquired in-process research and development write-off, while adjusted results were better than consensus. GILD Attractive Biotech Stock With Solid Base Revenue Growth
• Neutral Sentiment: Unusually heavy call-option buying points to increased bullish trading interest, but options activity is speculative and does not by itself change Gilead’s fundamentals.
• Neutral Sentiment: Coverage of Gilead’s second-quarter earnings call may provide additional details on pipeline progress and management priorities, though no specific new financial catalyst was provided in the supplied report. Analyst Questions From Gilead’s Q2 Earnings Call
• Negative Sentiment: Erste Group Bank slightly reduced its FY2026 EPS forecast to a $0.75 loss from a $0.74 loss and trimmed its FY2027 estimate to $9.57 from $9.59. Although the changes are small, they indicate mildly softer expectations and contrast with the $0.50 consensus loss forecast for the current year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 82,000 shares of company stock valued at $10,641,790. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on GILD. Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Barclays dropped their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Finally, Daiwa Securities Group reduced their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $135.87 on Thursday. The business’s 50-day simple moving average is $129.75 and its two-hundred day simple moving average is $136.42. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The stock has a market cap of $168.47 billion, a PE ratio of -50.89 and a beta of 0.32. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter last year, the business posted $2.01 earnings per share. The firm’s revenue was up 10.6% on a year-over-year basis. As a group, analysts forecast that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.